Nicotine and endogenous opioids: Toward specific pharmacotherapy

Canadian Journal of Psychiatry

Volumn 43, Issue 1, 1998, Pages 37-42

  Ismail, Zahinoor ^a,c   El Guebaly, Nady ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Comorbidity; Endogenous opioids; Naltrexone; Nicotine; Opioid antagonism; Smoking cessation

Indexed keywords

CYPRODIME; DOPAMINE; ENDORPHIN; LY 255582; MU OPIATE RECEPTOR; NALOXONE; NALTREXONE; NICOTINE; OPIATE ANTAGONIST; QUADAZOCINE; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DOPAMINE RELEASE; DRUG ANTAGONISM; DRUG EFFICACY; HUMAN; NEUROMODULATION; ORAL DRUG ADMINISTRATION; PSYCHOPHYSIOLOGY; REINFORCEMENT; REVIEW; SMOKING; SUBCUTANEOUS DRUG ADMINISTRATION; WITHDRAWAL SYNDROME;

EID: 0031894405     PISSN: 07067437     EISSN: None     Source Type: Journal    
DOI: 10.1177/070674379804300103     Document Type: Review

References (63)

1. Coambs RB, Kozlowski LT, Ferrence RG. The future of tobacco use and smoking research. In: Ney T, Gale A, editors. Smoking and human behaviour. New York: Wiley; 1989. p 337-48.
2. Hughes JR. Possible effects of smoke-free inpatient units on psychiatric diagnosis and treatment. J Clin Psychiatry 1993;54:109-14.
3. Breslau N. Psychiatric comorbidity of smoking and nicotine dependence. Behav Genet 1995:25:95-101.
4. Hall SM, Munoz RF, Reus VI, Sees KL. Nicotine, negative affect, and depression. J Consult Clin Psychol 1993;61:761-7.
5. Glassman AH, Stetner F, Walsh BT, Raizman PS, Fleiss JL, Cooper TB, and others. Heavy smokers, smoking cessation, and clonidine: results of a doubleblind, randomized trial. JAMA 1988;259:2863-6.
6. Hughes JR, Frances RJ. How to help psychiatric patients stop smoking. Psychiatric Serv 1995;46:435-7.
7. Hughes JR, Hatsakami DK, Mitchell JE, Dahlgren LA. Prevalence of smoking among psychiatric outpatients. Am J Psychiatry 1986; 143:993-7.
8. Lavin MR, Siris SG, Mason SE. What is the clinical importance of cigarette smoking in schizophrenia? Am J Addict 1996;5:189-208.
9. el-Guebaly N, Hodgins DC. Schizophrenia and substance abuse: prevalence issues. Can J Psychiatry 1992;37:704-10.
10. Yassa R, Lal S, Korpassy A, Ally J. Nicotine exposure and tardive dyskinesia. Biol Psychiatry 1987;22:67-72.
11. Pomerleau CS, Ehrlich E, Tate JC, Marks JL, Flessland KA, Pomerleau OF. The female weight-control smoker: a profile. J Subst Abuse 1993;5:391-400.
12. Hughes JR. An overview of nicotine use disorders for alcohol/drug abuse clinicians. Am J Addict 1996:5:262-74.
13. Fagerstrom KO, Schneider NG. Measuring nicotine dependence: a review of the Fagerstrom tolerance questionnaire. J Behav Med 1989; 12:159-82.
14. Goldberg SR, Stolerman IP, editors. Behavioral analysis of drug dependence. Orlando: Academic Press; 1986.
15. Stolerman IP, Shoaib M. The neurobiology of tobacco addiction. Trends Pharmacol Sci 1991;12:467-73.
16. Jarvik ME. The role of nicotine in the smoking habit. In: Hunt WA, editor. Learning mechanisms in smoking. Chicago: Aldine; 1970. p 155-90.
17. Russell MAH, Feyerabend C. Cigarette smoking: a dependence on high-nicotine boli. Drug Metab Rev 1978;8:29-57.
18. United States Department of Health and Human Services. The health consequences of smoking: nicotine addiction. 1988 report of the surgeon general. Rockville (MD): Public Health Service; 1988.
19. Benowitz NL. Cigarette smoking and nicotine addiction. Med Clin North Am 1992;76:415-37.
20. Henningfield JE, Keenan RM. Nicotine delivery kinetics and abuse liability. J Consult Clin Psychol 1993;61:743-50.
21. Koob GF. Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci 1992;13:177-84.
22. Glickman SE, Schiff BB. A biological theory of reinforcement. Psychol Rev 1967;74:81-109.
23. Wise RA. The role of reward pathways in the development of drug dependence. Pharmacology and Therapeutics 1987;35:227-63.
24. Nisell M. Nicotine dependence, midbrain dopamine systems and psychiatric disorders. Pharmacology and Toxicology 1995;76:157-62.
25. DiChiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A 1988;85:5274-8.
26. Gratton A. In vivo analysis of the role of dopamine in stimulant and opiate self-administration. J Psychiatry Neurosci l996;21:264-79.
27. Yoshida M, Yokoo H, Tanaka T, Mizoguchi K, Emoto H, lshii H, and others. Facilitatory modulation of mesolimbic dopamine neuronal activity by a μ-opioid agonist and nicotine as examined with in vivo microdialysis. Brain Res 1993;624:277-80.
28. 3H] dopamine release by nicotine in rat nucleus accumbens. J Neurochem 1987;49:1449-54.
29. Imperato A, Muks A, Di Chiara G. Nicotine preferentially stimulates dopamine release in the limbic system of freely moving rats. Eur J Pharmacol 1986; 132:337-8.
30. Brazell MP, Mitchell SN, Joseph MH, Gray JA. Acute administration of nicotine increases the in vivo extracellular levels of dopamine, 3,4dihydroxyphenyl acetic acid and ascorbic acid preferentially in the nucleus accumbens of the rat: comparison with caudate putamen. Neuropharmacology 1990;29:1177-85.
31. Corrigall WA, Coen KM, Adamson KL. Self-administered nicotine activates the mesolimbic dopamine system through the ventral tegmental area. Brain Res 1994;653:278-84.
32. Pomerleau OF, Pomerleau CS. Neuroregulators and the reinforcement of smoking: towards a biobehaviorai explanation. Neurosci Biobehav Rev 1984;8:503-13.
33. Pomerleau OF, Fertig JB, Seyler LE, Jaffe J. Neuroendocrine reactivity to nicotine in smokers. Psychopharmacology 1983;81:61-7.
34. Pierczchala K, Houdi AA, Van Loon GR. Nicotine-induced alterations in brain regional concentrations of native and cryptic Met and Leu-enkephalins. Peptides 1987;8:1035-43.
35. Houdi AA, Pierczchala K, Marson L, Palkovits, Van Loon GR. Nicotine-induced alteration in Tyr-Gly-Gly and methionine-enkephalin in discrete brain nuclei reflects altered enkephalin neuron activity. Peptides 1991;12:161-6.
36. Dhatt RK, Gudehithlu KP, Wemlinger TA, Tejwani GA, NefFNH, Hadjiconstantinou M. Preproenkephalin mRNA and methionine-enkephalin content are increased in mouse striatum after treatment with nicotine. J Neurochem 1995;64:1878-83.
37. Davenport K, Houdi AA, Van Loon GR. Nicotine protects against μ-opioid receptor antagonism by β-funaltrexamine: evidence for nicotine-induced release of endogenous opioids in brain. Neurosci Lett 1990;113:40-6.
38. Simon EJ. Opiates: neurobiology in substance abuse. A comprehensive textbook. Baltimore: Williams and Wilkins; 1992. p 195-204.
39. Mansour A, Khachaturian H, Lewis ME, Akil H, Watson SS. Autoradiographic differentiation of μ, δ, and κ opioid receptors in the rat forebrain and midbrain. J Neurosci 1987;7:2445-64.
40. Tempel A, Zukin RS. Neuroanatomical patterns of the μ,δ 5 and κ opiod receptors of rat brain as determined by quantitative in vitro radiography. Proc Natl Acad Sci U S A 1987;84:4308-12.
41. Pleuvry BJ. Opioid receptors and their ligands: natural and unnatural. British Journal of Anaesthesia 1991;66:370-80.
42. Pasternak G. High and low affinity opioid binding sites: relationship to μ and δ sites. Life Sci 1982:31:1303-6.
43. Fowler CJ, Fraser GL. μ-, δ-, κ-opioid receptors and their subtypes. A critical review with emphasis on radioligand binding experiments. Neurochem Int 1994;24:401-26.
44. Ling GS, Spiegel K, Nishimura SL, Pasternak G. Dissociation of morphine's analgesic and respiratory depressant actions. Eur J Pharmacol 1983;86:487-8.
45. Aceto MD, Scates SM, Ji Z, Bownan ER. Nicotine's opioid and anti-opioid interactions: proposed role in smoking behaviour. Eur J Pharmacol 1993;248:333-5.
46. Malin DH. Naloxone precipitates nicotine abstinence syndromes in the rat. Psychopharmacology 1993; 112:339-42.
47. Corrigall WA, Herling S, Coen KM. Evidence for opioid mechanisms in the behavioral effects of nicotine. Psychopharmacology 1988;96:29-35.
48. Mello NK, Mendelson JH, Sellers ML, Kuehnle JC. Effects of heroin self-administration on cigarette smoking. Psychopharmacology 1980;67:45-52.
49. Chait LD, Griffiths RR. Effects of methadone on human cigarette smoking and subjective ratings. J Pharmacol Exp Ther 1984;229:636-40.
50. Karras A, Kane JM. Naloxone reduces cigarette smoking. Life Sci 1980;27:1541-5.
51. Palmer RF, Berens A. Double blind study of the effect of naloxone on the pleasure of cigarette smoking [abstract]. Federation Proceedings 1983;42:2116.
52. Nemeth-Coslett R, Griffiths RR. Naloxone does not affect cigarette smoking. Psychopharmacology 1986;89:261-4.
53. Gorelick DA, Rose J, Jarvik M. Effect of naloxone on cigarette smoking. J Subst Abuse 1989;1:153-9.
54. Sutherland G, Stapleton JA, Russell MAH, Feyerabend C. Naltrexone, smoking behaviour and cigarette withdrawal. Psychopharmacology 1995; 120:418-25.
55. O'Brien CP. Is nicotine different from other addictions? American Psychiatric Association 149th annual meeting continuing medical education syllabus and scientific proceedings 1996;34b:318.
56. Hughes JR. Treatment for nicotine dependence: does it work? American Psychiatric Association 149th annual meeting continuing medical education syllabus and scientific proceedings 1996;34d:318.
57. Covey LS, Glassman AH. New approaches to smoking cessation. Drug Therapy 1990;20:55-61.
58. O'Malley S. Integration of opioid antagonists and psychosocial therapy in the treatment of narcotic and alcohol dependence. J Clin Psychiatry 1995;56(7 Suppl):30S-38S.
59. [Anonymous]. Nalmefene-a long-acting injectable opioid antagonist. Med Lett Drugs Ther 1995;37:97-8.
60. Mason BJ, Ritvo EC, Morgan RO, Salvato FR, Goldberg G, Welch B, and others. A double-blind, placebo controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence. Alcohol Clin Exp Res -1994;18:1162-7.
61. Horan PJ, de Costa BR, Rice K, Haaseth RC, Hruby VJ, Porneca F. Differential antagonism of bremazocine and U69, 593-induced antinociception by quadazocine: further functional evidence of opioid kappa receptor multiplicity in the mouse. J Pharmacol Exp Ther 1993;266:926-33.
62. Swanson SF, Callow J, Pohland RC, Chay SH, Johnson T. Disposition of the opioid antagonist, LY255582, in rats and dogs. Drug Metabolism and Disposition 1995;23:916-21.
63. Schmidhammer H,Jennewein HK,Krussnig Roland,Traynor JR,PatelD, BellK, and others. Synthesis and biological evaluation of 14-Alkoxymorphinans. 11. 3-Hydroxycyprodime and analogues: opioid antagonist profiles in comparison to cyprodime. J Med Chem 1995;38:3071-7.